ALECNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Alector, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.95+0.11 (+5.98%)
Close on Oct 19, 2026
- Market cap
- $216.89M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2016 to 2025
Operating margin
-741.3%+183.8 pts over 5 years
Net margin
-679.2%+222.5 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -79.1% | -46.0% | -0.1% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -82.3% | -181.6% | |
| Return on assets | – | -41.8% | -37.5% | |
| Current ratio | – | 6.19 | 3.83 | |
| Debt to equity | – | – | 0.33 | |
| Net debt to EBITDA | – | – | 0.37× | |
| Capex to revenue | – | 23.9% | 0.2% | |
| Diluted shares | – | 78M | 103M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Alector generated $916.98M from operations and spent $11.04M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$916.98M
Used
$11.04M
Capital expenditure$11.04M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-679.2%
×Asset turnover0.06×
×Equity multiplier4.84×
=Return on equity, FY2025-181.6%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -679.2% | 0.06× | 4.84× | -181.6% |
| FY2024 | -118.4% | 0.18× | 4.18× | -91.2% |
| FY2023 | -134.3% | 0.14× | 4.04× | -74.8% |
| FY2022 | -99.8% | 0.17× | 3.11× | -51.8% |
| FY2021 | -17.5% | 0.32× | 2.29× | -12.8% |
| FY2020 | -901.6% | 0.05× | 1.97× | -82.3% |
| FY2019 | -496.7% | 0.06× | 7.50× | -216.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$142.93M
- Cash generatingOperating cash flow above zero-$184.03M
- Return on assets improvedROA up on the prior year-19.1% → -30.5%
- Earnings backed by cashOperating cash flow above net income-$184.03M vs -$142.93M
- Less leverageLong-term debt to assets fell2.0% → 3.2%
- Better liquidityCurrent ratio rose3.40 → 3.83
- No dilutionShare count did not rise97M → 103M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.16 → 0.04